Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 8/20 | 1.00 |
| ▸ | EGFR | P00533 | 11/20 | 0.98 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.98 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.98 |
| ▸ | KDR | P35968 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | GAK | O14976 | 1/20 | 0.78 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.78 |
| ▸ | ABL1 | P00519 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CDK1 | P06493 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | SRC | P12931 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12963484 | 0.95 | FBP1 (0.91) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL30363011 | 0.88 | EGFR (1.00) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL29444884 | 0.88 | EGFR (1.00) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL9423 | 0.88 | EGFR (1.00) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL8349430 | 0.88 | EGFR (0.91) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL2100996 | 0.86 | EGFR (0.77) | FBP1EGFRERBB2ERBB4 | |
| Hydrochloric Acid SCHEMBL93918 | 0.86 | EGFR (1.00) | FBP1EGFRERBB2ERBB4KDR | |
| Hydrochloric Acid SCHEMBL29369196 | 0.86 | EGFR (1.00) | FBP1EGFRERBB2ERBB4KDR | |
| Hydrochloric Acid SCHEMBL30362813 | 0.86 | EGFR (1.00) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL5742396 | 0.86 | EGFR (0.86) | FBP1EGFRERBB2ERBB4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20130164847-A1 | USE OF A PROTEIN TYROSINE KINASE INHIBITOR FOR INDUCING THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARDIOGENIC CELLS | PHARMICELL. CO., LTD. (KR) | 2013-06-27 | — | — | US | claimed |
| CN-103140579-A | Use of a protein tyrosine kinase inhibitor for inducing the differentiation of mesenchymal stem cells into cardiogenic cells | PHARMICELL CO LTD | 2013-06-05 | — | — | CN | claimed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2003-05-01 | — | — | US | claimed |
| EP-1201765-A2 | Cellular kinases involved in cytomegalovirus infection and their inhibition | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-05-02 | — | — | EP | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-10034931-B2 | Use of EGFR pathway inhibitors to increase immune responses to antigens | EMORY UNIVERSITY (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20160228533-A1 | Use of EGFR Pathway Inhibitors to Increase Immune Responses to Antigens | EMORY UNIVERSITY (US) | 2016-08-11 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006017317-A2 | METHOD FOR THE TREATMENT OF DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2006-02-16 | — | — | WO | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-6849409-B2 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2005-02-01 | — | — | US | disclosed |
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2003-05-01 | — | — | US | disclosed |
| EP-1201765-A2 | Cellular kinases involved in cytomegalovirus infection and their inhibition | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | CDC42BPG, CDC42BPB, CDC7 | FBP1 2277/4885EGFR 3100/4885ERBB2 1371/4885 |
| US-20130164847-A1 | USE OF A PROTEIN TYROSINE KINASE INHIBITOR FOR INDUCING THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARDIOGENIC CELLS | MYLK2, PTK2B, TTK | FBP1 3026/4885EGFR 1042/4885ERBB2 235/4885 |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | FBP1 954/4885EGFR 411/4885ERBB2 494/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | FBP1 954/4885EGFR 411/4885ERBB2 494/4885 |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | FBP1 1906/4885EGFR 1445/4885ERBB2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.